Natalie Torok, M.D., M.Sc.

Natalie J. Torok, M.D., M.Sc.

Specialties

Gastroenterology and Hepatology

Internal Medicine

Transplant Hepatology

Title

  • Professor
  • Professor, VA Northern California Health Care System, Mather, CA
To see if Natalie J. Torok is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Medical Group - Sacramento (J Street)

2825 J St., Suite 400
Sacramento, CA 95816
Driving Directions

Primary Phone:
916-734-2737

UC Davis Medical Group - Folsom

271 Turn Pike Dr.
Folsom, CA 95630
Driving Directions

Primary Phone:
916-985-9300

Additional Phone Numbers

Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Philosophy of Care

As a hepatologist and certified transplant hepatologist, I take care of patients with end-stage liver disease and also provide post-transplant care, including management of immunosuppression and treatment of post-transplant hepatitis C.

I see patients with nonalcoholic steatohepatitis (NASH), alcoholic liver disease, and autoimmune hepatitis. Also, we provide comprehensive care for patients with hepatocellular carcinoma.

Clinical Interests

Dr. Torok's clinical interests include; Gastroenterology and Hepatology, Transplant Hepatology, and Internal Medicine.

Research/Academic Interests

Our research focuses on wound healing and the basic mechanism of fibrosis in the liver.  We explore the pathways linking chronic liver injury, hepatocyte death and the activation of hepatic stellate cells, the principle fibrogenic cells of the liver.  

Our investigations led to the discovery of the important role of the NADPH oxidases in stellate cell activation and the production of oxidative radicals.  Based on our findings our aim is to explore the specific role of NADPH oxidases in non-alcoholic steatohepatitis and alcoholic liver disease.  Our ultimate goal is to move towards translational studies and to develop new therapies for patients with liver fibrosis and cirrhosis. 

Division

Gastroenterology and Hepatology

Center/Program Affiliation

UC Davis Medical Group

Education

M.D., Semmelweis Medical University, Budapest, 1988

M.Sc., Cellular and Molecular Biology, Cancer Research Institute of Laval University, Quebec Canada 1992

B.Sc., Verseghy Gimn?zium, Szolnok Hungary 1982

Residency

Semmelweis University , Budapest , 1988-1990

Internal Medicine, Mayo Clinic , Rochester MN 1996-1999

Fellowships

Gastroenterology and Hepatology, Mayo Clinic , Rochester MN 1999-2003

Board Certifications

American Board of Internal Medicine, 2010

American Board of Internal Medicine, Gastroenterology and Hepatology, 2014

American Board of Internal Medicine, Transplant Hepatology, 2008

Professional Memberships

American Association for the Study of Liver Disease

American College of Physicians

American Gastroenterlogical Association

American Liver Foundation

American Society for Clinical Investigation

Honors and Awards

Associate Editor, American Journal of Physiology, Gastrointestinal and Liver Physiology, 2015

Elected to the American Society for Clinical Investigation, 2014

Boris Ruebner and John Rosenquist Excellence in Teaching Award, UC Davis, GI and Hepatology, 2014

Richard C. Woodard Award, UC Davis Mentor, 2014

Internal Medicine-Pathology-Surgery Research Award, UC Davis, 2012

University of California, Cancer Research Coordinating Committee Award, 2006

Select Recent Publications

Torok NJ: Update on Alcoholic Hepatitis. Biomolecules,  2015 Nov 2;5(4):2978-86.

Bettaieb A, Jiang JX, Sasaki Y, Chao TI, Kiss Z, Chen X, Tian J, Katsuyama M, Yabe-Nishimura C, Xi Y, Szyndralewiez C, Schröder K, Shah A, Brandes RP, Haj FG and Török NJ: “Hepatocyte NADPH Oxidase 4 Regulates Stress Signaling, Fibrosis, and Insulin Sensitivity during Development of Steatohepatitis in Mice”, Gastroenterology, 2015;Aug;149(2):468-480.

Torok NJ, JA. Dranoff, D. Schuppan and SL. Friedman: “Strategies and Endpoints of Antifibrotic Drug Trials” Hepatology, 2015;Aug;62(2):627-34.

Jiang JX, Torok NJ: ” MLK3 as a regulator of disease progression in NASH”. Liver Int. 2014 Apr 1.

Jiang XJ, Chen, X, Fukada, H, Serizawa, N, Devaraj, S, and Török, NJ:  Advanced glycation end products induce fibrogenic activity in NASH by modulating the TNF? converting enzyme activity in mice. Hepatology, 2013, Oct;58(4):1339-48.